Now Recruiting Dogs with Babesia gibsoni
Principle Investigator
Description
NC State College of Veterinary Medicine is enrolling dogs with Babesia gibsoni in a trial to evaluate if the use of a new drug combination (atovaquone/proguanil hydrochloride, azithromycin, and artemisinin) can improve treatment outcomes.
A new treatment regimen using atovaquone/proguanil hydrochloride, azithromycin, and an artemisinin derivative has recently been shown to improve treatment outcomes in Babesia gibsoni infected dogs
Advantages of this protocol included once a day administration, decreased cost, and the potential to help overcome resistance due to inclusion of artemisinin and proguanil hydrochloride
Testing Requirements
All dogs will receive 10 doses of artemisinin, atovaquone/proguanil hydrochloride, and azithromycin over a 10-day period.
Your dog will be evaluated by your primary care veterinarian or at NCSU up to 6 times over a four-month period for physical examinations and/or laboratory testing.
Enrollment Start
04/12/2024
Enrollment Finish
04/12/2025
Eligibility
Must be diagnosed with Babesia gibsoni by PCR at NC State Vector Borne Disease Lab
Must not have received treatment for Babesia gibsoni within 90 days of enrolling in the trial
Must not require hospitalization or blood transfusions for the treatment of Babesia gibsoni
Must weigh at least 3 kg (6.6lbs) and be over one year of age
Flyer
Contact
For more information, please contact: CVMClinicalStudies@ncsu.edu
- Categories:
